Glucose as a Mediator of Self-control Performances in Patients With Schizophrenia

Schizophrenia Clinical Trial

Official title:

Glucose as a Mediator of Self-control Performances in Patients With Schizophrenia: A Randomized Controlled Study

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT01563016
• Other study ID #: selfcontrolvsglucose
• Status: Not yet recruiting
• Phase: N/A
• First received: March 22, 2012
• Last updated: March 23, 2012
• Start date: April 2012
• Est. completion date: April 2013

Study information

• Verified date: March 2012
• Source: The University of Hong Kong
• Contact: Eric YH Chen, MD
• Phone: 852-22553063
• Email: eyhchen[@]hku.hk
• Is FDA regulated: No
• Health authority: Hong Kong: Ethics Committee
• Study type: Interventional

Clinical Trial Summary

The research aims to investigate the relationship between self-control ability and blood glucose level in schizophrenic patients. The main purpose of the present study is to explore whether the close relationship of blood glucose and self-regulatory strength observed in healthy individuals, is applicable to schizophrenic patients. More specifically, the current study aims

• to investigate whether the exertion of self-control reduces blood glucose,

• to examine whether low level of blood glucose deteriorates subsequent self-control performances

• to examine whether restoring the glucose level eliminates these impairments, in schizophrenic patients.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 100
• Est. completion date: April 2013
• Est. primary completion date: April 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 15 Years and older

Eligibility

Inclusion Criteria:

• Aged 15 or above

• DSM-IV diagnosis of schizophrenia, schizoaffective disorder, schizophreniform psychosis, brief psychosis, psychosis NOS or delusional disorder

• Cantonese-speaking Chinese

• Ability to understand the nature of the study and sign informed consent

Exclusion Criteria:

• Organic Brain disorder

• Known history of intellectual disability

• Priority Follow Up (Subtarget or Target)

• All allergic to any sugar or artificial sweeteners

• Diabetics

• Physical Disability

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Schizophrenia

Intervention

Dietary Supplement:
• glucose drink
participants will receive a drink rich in glucose

Locations

Country	Name	City	State
China	The University of Hong Kong	Hong Kong

Sponsors (2)

Lead Sponsor	Collaborator
The University of Hong Kong	Queen Mary Hospital, Hong Kong

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Blood Glucose Level		baseline, after depleting task	No
Primary	self control tasks (handgrip, stroop, figure tracing task)		after 12-minutes metabolizing phase	No